Boundless Bio, Inc.
No enriched coverage for $BOLD in the last 7 days.
TANG KEVIN purchased 21,640 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.39 ($2.38–$2.40) across 3 trades over 2026-10-22 to 2026-10-26. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).
Insider trading activity for US-listed stocks on Tuesday included significant purchases and sales. Saba Capital bought 338,104 shares of BNY Mellon Strategic Municipals (LEO) at $5.63-$5.67. Nippon Life bought 347,195 shares of Corebridge Financial (CRBG) at $34.31-$35.07. Kevin Tang increased his stake in Boundless Bio (BOLD) with purchases totaling $349,592. Smriti Popenoe bought $156,560 of Dynex Capital (DX) stock. David Sims acquired $108,632 of Eagle Capital Growth Fund (GRF) shares.
TANG KEVIN purchased 149,474 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.34 ($2.33–$2.37, $0.35M total) across 4 trades over 2026-10-16 to 2026-10-20. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).
Recent BOLD coverage spans insider activity, financial news and market movers.
In the last 30 days, BOLD insiders filed 7 SEC Form 4 transactions — 7 purchases ($401K) and no sales. The most active reporter was TANG KEVIN with 7 filings.
The purchase may signal confidence from a major owner, potentially supporting the stock price.
Minor insider buy may provide slight support.
The purchase signals confidence from a 10% owner, likely supporting short-term price upside.
Positive merger and capital raise likely boost valuation.
Amendment may affect share dilution, warrant issuance and post‑merger ownership structure.
AlphAI scores every news story that mentions BOLD with an AI model for sentiment and relevance, and aggregates insider trades from Boundless Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TANG KEVIN purchased 21,640 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.39 ($2.38–$2.40) across 3 trades over 2026-10-22 to 2026-10-26. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).
1 min readInsider trading activity for US-listed stocks on Tuesday included significant purchases and sales. Saba Capital bought 338,104 shares of BNY Mellon Strategic Municipals (LEO) at $5.63-$5.67. Nippon Life bought 347,195 shares of Corebridge Financial (CRBG) at $34.31-$35.07. Kevin Tang increased his stake in Boundless Bio (BOLD) with purchases totaling $349,592. Smriti Popenoe bought $156,560 of Dynex Capital (DX) stock. David Sims acquired $108,632 of Eagle Capital Growth Fund (GRF) shares.
3 min readTANG KEVIN purchased 149,474 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.34 ($2.33–$2.37, $0.35M total) across 4 trades over 2026-10-16 to 2026-10-20. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).
1 min readBoundless Bio (BOLD) and Backblaze (BLZE) stocks surged 85% and 43% respectively, while Quantinuum (QNT) gained 13%. BOLD rose after a merger deal with Serapha Bio, including $230M in funding. BLZE reached a 2-year high after a $335M AI cloud deal. QNT hit a record high following a White House quantum tech development order.
2 min readBoundless Bio, Inc. (BOLD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously announced, on June 22, 2026, Boundless Bio, Inc., a Delaware corporation (“Boundless Bio”), Boulder Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Boundless Bio (“Merger Sub”), and Seraph
2 min readSeveral biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
3 min readTANG KEVIN purchased 63,969 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.43 ($2.43–$2.44, $0.16M total) across 3 trades over 2026-07-14 to 2026-07-16.
2 min readTANG KEVIN purchased 91,585 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.42 ($2.42–$2.48, $0.22M total) across 3 trades over 2026-07-09 to 2026-07-13.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readTANG KEVIN purchased 57,210 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.48 ($2.46–$2.49, $0.14M total) across 3 trades over 2026-07-06 to 2026-07-08.
2 min read